Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908886 | 0.92 | ALDH1A1 (0.40) | ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL27013497 | 0.90 | ALDH1A1 (0.39) | ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL8814117 | 0.83 | — | — | |
| SCHEMBL2625547 | 0.82 | NLRP3 (0.38) | ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL21025101 | 0.79 | PMP22 (0.34) | — | |
| SCHEMBL23542140 | 0.77 | ALDH1A1 (0.33) | ALDH1A1LMNATP53NLRP3 | |
| SCHEMBL18487512 | 0.77 | — | — | |
| SCHEMBL12384260 | 0.76 | — | — | |
| SCHEMBL12424218 | 0.76 | CA2 (0.33) | LMNA | |
| SCHEMBL8620435 | 0.76 | APP (0.46) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | UNIV ROCKEFELLER (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-11040028-B2 | Penicinotam derivative, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-06-22 | — | — | US | disclosed |
| US-10838301-B2 | Resist composition, method of forming resist pattern, fluorine-containing compound, and compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-07-24 | — | — | US | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2548877-A1 | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors | MSD Oss B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080064071-A1 | Thermostability; fusion proteins; kits | AGILENT TECHNOLOGIES, INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | EGFR, ERBB2, WEE1 | ALDH1A1 2834/4885LMNA 4796/4885TP53 21/4885 |
| US-10838301-B2 | Resist composition, method of forming resist pattern, fluorine-containing compound, and compound | AFF1, RER1, AFF2 | ALDH1A1 1349/4885LMNA 1288/4885TP53 4000/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4709/4885LMNA 3425/4885TP53 915/4885 |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | ALDH1A1 4836/4885LMNA 4521/4885TP53 648/4885 |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | ALDH1A1 2666/4885LMNA 805/4885TP53 210/4885 |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | ALDH1A1 2506/4885LMNA 4790/4885TP53 147/4885 |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | ALDH1A1 3197/4885LMNA 3278/4885TP53 656/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | ALDH1A1 226/4885LMNA 4510/4885TP53 925/4885 |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | ALDH1A1 178/4885LMNA 4387/4885TP53 4317/4885 |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | LSS, NRDC, SPOUT1 | ALDH1A1 4234/4885LMNA 4548/4885TP53 4340/4885 |
| US-11040028-B2 | Penicinotam derivative, preparation method and use thereof | TPMT, MAPT, TLR4 | ALDH1A1 1738/4885LMNA 2825/4885TP53 826/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | ALDH1A1 115/4885LMNA 4039/4885TP53 937/4885 |
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | MAVS, ZC3HAV1, SARS1 | ALDH1A1 1983/4885LMNA 3207/4885TP53 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.